Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses.
Publication Title
JACC Cardiovasc Interv
Document Type
Article
Publication Date
7-8-2019
Abstract
OBJECTIVES: A large comprehensive analysis of transcatheter aortic valve replacement (TAVR) was performed for failed stentless bioprostheses.
BACKGROUND: Valve-in-valve (ViV) transcatheter aortic replacement (TAVR) is an alternative to redo surgery for patients with a failing aortic bioprosthesis.
METHODS: Unadjusted outcome data were collected from the VIVID (Valve-in-Valve International Data) registry between 2007 and 2016 from a total of 1,598 aortic ViV procedures (291 stentless, 1,307 stented bioprostheses).
RESULTS: Bioprosthetic failure was secondary to aortic regurgitation in 56% of stentless and 20% stented devices (p < 0.001). ViV-TAVR access was transfemoral in 71.1% stentless and 74.2% stented ViV-TAVR. Self-expanding devices were more frequently used in stentless ViV-TAVR (56.0% vs. 39.9%; p = 0.05), but there was no difference between balloon-expanding and self-expanding TAVR devices for stented ViV-TAVR (48.6% vs. 45.1%). The degree of oversizing for all mechanisms of bioprosthesis failure was 9 ± 10% for stentless ViV-TAVR vs. 6 ± 9% for stented ViV-TAVR (and 8 ± 10% for stentless ViV-TAVR vs. 3 ± 9% for stented ViV-TAVR in patients with predominant aortic regurgitation; both p < 0.001). Initial device malposition (10.3% vs. 6.2%; p = 0.014), second transcatheter device (7.9% vs. 3.4%), coronary obstruction (6.0% vs. 1.5%), and paravalvular leak occurred more frequently in stentless ViV-TAVR (all p < 0.001). Hospital stay duration (median 7 days) was no different, and 30-day (6.6% vs. 4.4%; p = 0.12) and 1-year mortality year (15.8% vs. 12.6%; p = 0.15) were numerically higher, but not statistically different, after stentless ViV-TAVR.
CONCLUSIONS: Stentless ViV-TAVR is associated with greater periprocedural complications (initial device malposition, second transcatheter device, coronary obstruction, paravalvular leak), but no difference in 30-day and 1-year outcome.
Clinical Institute
Cardiovascular (Heart)
Specialty
Cardiology
Recommended Citation
Duncan, Alison; Moat, Neil; Simonato, Matheus; de Weger, Arend; Kempfert, Jorg; Eggebrecht, Holger; Walton, Antony; Hellig, Farrel; Kornowski, Ran; Spargias, Konstantinos; Mendiz, Oscar; Makkar, Raj; Guerrero, Mayra; Rihal, Charanjit; George, Isaac; Don, Creighton; Iadanza, Alessandro; Bapat, Vinayak; Welsh, Robert; Wijeysundera, Harindra C; Wood, David; Sathananthan, Janarthanan; Danenberg, Haim; Maisano, Francesco; Garcia, Santiago; Gafoor, Sameer; Nombela-Franco, Luis; Cobiella, Javier; and Dvir, Danny, "Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses." (2019). Articles, Abstracts, and Reports. 1731.
https://digitalcommons.providence.org/publications/1731
